64x Bio

The landscape of medicine is rapidly evolving, yet the ability to scale groundbreaking therapies remains a significant hurdle. Many promising advancements in next-generation treatments face limitations due to manufacturing bottlenecks. While scientific progress is accelerating, the necessary infrastructure lags behind, hindering widespread adoption and patient access.

64x Bio addresses this critical challenge with VectorSelect, a platform designed to unlock the scalability potential of these vital therapies. By integrating massively parallelized screening methodologies with advanced computational analysis, VectorSelect engineers high-yield cell lines and optimizes production technologies. This comprehensive approach accelerates the manufacturing processes of advanced therapies from the foundational level, paving the way for a more accessible and efficient healthcare future.